Methylprednisolone combined with intrathecal injection with methotrexate plus dexamethasone for treatment of Neuropsychiatric lupus

曾卫东,左晓霞,游运辉,罗卉

DOI: https://doi.org/10.3969/j.issn.1005-8982.2004.16.042

2004-01-01

Abstract:Objective: To investigate the effect, side effect, relapse rate and mortality rate of methylprednisolone (MP) combined with intrathecal injection (i.t) with methotrexate (MTX) plus dexamethasone (DXM) in treating central nervous system involvement in systemic lupus erythematosus (CNS-SLE). Methods: Thirteen CNS lupus patients who were given MP (500 mg) for three days combined with intrathecal injection with MTX plus DXM were compared with fifteen CNS lupus patients treated only with MP (1000 mg) during the period of year 1990~1999. Results: For the patients in the group of MP (1000 mg), +i.t, the improvement rate in two days was 92.3%, whereas in the group of MP (500 mg), it was 84.6%; short-term side effects after treatment: MP (500 mg) +i.t, 0%; while MP (1000 mg), 20%. Both groups were followed up for 3 months to 3 years. The relapse rate in the two groups were 15.4%; [MP (500 mg)+ i.t] and 33.3% [MP (1000 mg)], respectively. In addition, the mortality rate was 7.7% in the group of MP (500 mg)+i.t, compared with 33.3% in the group of MP (1000 mg). Conclusion: MP (500 mg) combined with i.t with MTX puls DXM is a promising method for treating CNS lupus with better clinical effect, fewer side effects and lower relapse and mortality rate.